# OnCo record nct06271837 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06271837/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06271837", "NCT06271837" ;
  schema:name "A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors"@en ;
  schema:alternateName "DESTINY PanTumor03"@en ;
  schema:description "A phase 2 trial of Trastuzumab deruxtecan and Bevacizumab in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06271837/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06271837> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-02-22" ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/gastric-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/daiichi-sankyo/> .